Trelleborg Healthcare & Medical is investing to expand its European biopharmaceutical manufacturing capabilities in Malta, adding a fourth block to its current three onsite buildings. The site will initially add over 4,000 sq ft of cleanroom space to its current capabilities and focus on silicone tubing and braided hose, with options to expand in the future.
The Malta site is one of the company’s largest manufacturing sites in Europe. With the site expansion, the European facility joins the BioParma Center of Excellence in Northborough, MA, as the company’s second biopharma-focused manufacturing space. Trelleborg said that construction on the site has already begun, and it expects the facility will be completed by the end of 2023, with production starting in early 2024.
“The investment is a key milestone in our biopharmaceutical strategy of being a global partner for growth,” said Florance Veronelli, global business development lead for biopharmaceutical at Trelleborg. “With increased capacity and local accessibility, we can offer our customers the same capabilities in two different regions. This results in shorter lead times, more flexibility, increased speed to market, and best cost, especially when it comes to customers with a large demand for bulky products like tubing.”
